Journal
JOURNAL OF PSYCHOPHARMACOLOGY
Volume 21, Issue 4, Pages 374-383Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0269881106072343
Keywords
TPA023; selective partial GABA agonist; memory; body sway; saccadic eye movements; sedation; benzodiazepines
Ask authors/readers for more resources
TPA023, a GABA(A) alpha 2,3 alpha subtype-selective partial agonist, is expected to have comparable anxiotytic efficacy as benzodiazepines with reduced sedating effects. The compound lacks efficacy at the al subtype, which is believed to mediate these effects. This study investigated the effects of 0.5 and 1.5 mg TPA023 and compared them with placebo and lorazeparn 2 mg (therapeutic anxioLytic dose). Twelve healthy male volunteers participated in this p[acebo-controlled, double-blind, doubledummy, four-way, cross-over study. Saccadic eye movements and visual analogue scales (VAS) were used to assess the sedative properties of TPA023. The effects on postural stability and cognition were assessed using body sway and a standardized battery of neurophysiotogicat memory tests. Lorazepam caused a significant reduction in saccadic peak velocity, the VAS alertness score and impairment of memory and body sway. TPA023 had significant dose dependent effects on saccadic peak velocity (85 deg/sec maximum reduction at the higher dose) that approximated the effects of torazepam. In contrast to lorazepam, TPA023 had no detectable effects on saccadic latency or inaccuracy. Also unlike torazepam, TPA023 did not affect VAS alertness, memory or body sway. These results show that the effect profile of TPA023 differs markedly from that of lorazeparn, at doses that were equipotent with regard to effects on saccadic peak velocity. Contrary to lorazepam, TPA023 caused no detectable memory impairment or postural imbalance. These differences reflect the selectivity of TPA023 for different GABA(A) receptor subtypes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available